BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - FRA:BRM - US1101221083 - Common Stock
40.445 EUR
+0.29 (+0.71%)
Taking everything into account, BRM scores 6 out of 10 in our fundamental rating. BRM was compared to 53 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. BRM is valued quite cheap, while showing a decent growth score. This is a good combination! Finally BRM also has an excellent dividend rating. These ratings would make BRM suitable for value and dividend investing!
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of 5.33%, BRM perfoms like the industry average, outperforming 52.83% of the companies in the same industry.
With a decent Return On Equity value of 28.96%, BRM is doing good in the industry, outperforming 75.47% of the companies in the same industry.
BRM has a Return On Invested Capital of 15.09%. This is amongst the best in the industry. BRM outperforms 81.13% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 14.46%.
The last Return On Invested Capital (15.09%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 15.09% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
Looking at the Profit Margin, with a value of 10.58%, BRM is in line with its industry, outperforming 49.06% of the companies in the same industry.
Looking at the Operating Margin, with a value of 30.27%, BRM belongs to the top of the industry, outperforming 81.13% of the companies in the same industry.
In the last couple of years the Operating Margin of BRM has declined.
With a decent Gross Margin value of 73.92%, BRM is doing good in the industry, outperforming 66.04% of the companies in the same industry.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
Compared to 1 year ago, BRM has less shares outstanding
Compared to 5 years ago, BRM has less shares outstanding
The debt/assets ratio for BRM is higher compared to a year ago.
2.2 Solvency
BRM has an Altman-Z score of 2.05. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.05, BRM is doing worse than 62.26% of the companies in the same industry.
The Debt to FCF ratio of BRM is 3.37, which is a good value as it means it would take BRM, 3.37 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.37, BRM is doing good in the industry, outperforming 60.38% of the companies in the same industry.
A Debt/Equity ratio of 2.56 is on the high side and indicates that BRM has dependencies on debt financing.
BRM has a Debt to Equity ratio of 2.56. This is amonst the worse of the industry: BRM underperforms 81.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.05 |
ROIC/WACC1.93
WACC7.83%
2.3 Liquidity
A Current Ratio of 1.21 indicates that BRM should not have too much problems paying its short term obligations.
The Current ratio of BRM (1.21) is worse than 60.38% of its industry peers.
BRM has a Quick Ratio of 1.11. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.11, BRM is doing good in the industry, outperforming 67.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 460.68% over the past year.
Measured over the past years, BRM shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
The Revenue has been growing slightly by 7.32% in the past year.
Measured over the past years, BRM shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
The Earnings Per Share is expected to grow by 36.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -4.99% on average per year.
EPS Next Y467.96%
EPS Next 2Y131.17%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue Next Year-1.07%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.54%
Revenue Next 5Y-4.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BRM is valuated cheaply with a Price/Earnings ratio of 7.11.
BRM's Price/Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 94.34% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.83. BRM is valued rather cheaply when compared to this.
BRM is valuated cheaply with a Price/Forward Earnings ratio of 7.66.
BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 92.45% of the companies in the same industry.
BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 32.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.11 | ||
| Fwd PE | 7.66 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 88.68% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaper than 96.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.51 | ||
| EV/EBITDA | 6.14 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BRM may justify a higher PE ratio.
A more expensive valuation may be justified as BRM's earnings are expected to grow with 73.61% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y131.17%
EPS Next 3Y73.61%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.32%, BRM is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.99, BRM pays a better dividend. On top of this BRM pays more dividend than 92.45% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.39, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.32% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
98.12% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP98.12%
EPS Next 2Y131.17%
EPS Next 3Y73.61%
FRA:BRM (11/7/2025, 7:00:00 PM)
40.445
+0.29 (+0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap82.32B
Revenue(TTM)48.30B
Net Income(TTM)5.05B
Analysts67.88
Price Target45.53 (12.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.32% |
Yearly Dividend2.09
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)2.41%
PT rev (3m)-4.22%
EPS NQ rev (1m)-9.73%
EPS NQ rev (3m)-9.81%
EPS NY rev (1m)-1.68%
EPS NY rev (3m)-2.69%
Revenue NQ rev (1m)0.47%
Revenue NQ rev (3m)1.51%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)2.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.11 | ||
| Fwd PE | 7.66 | ||
| P/S | 1.99 | ||
| P/FCF | 6.51 | ||
| P/OCF | 5.97 | ||
| P/B | 5.45 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.14 |
EPS(TTM)5.69
EY14.07%
EPS(NY)5.28
Fwd EY13.06%
FCF(TTM)6.21
FCFY15.35%
OCF(TTM)6.77
OCFY16.75%
SpS20.32
BVpS7.43
TBVpS-10.96
PEG (NY)0.02
PEG (5Y)N/A
Graham Number30.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 15.09% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 95.64% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.05 |
F-Score7
WACC7.83%
ROIC/WACC1.93
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y467.96%
EPS Next 2Y131.17%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year-1.07%
Revenue Next 2Y-4.7%
Revenue Next 3Y-3.54%
Revenue Next 5Y-4.99%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 10 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 467.96% in the next year.